Metraipolis › archive › dc_06ca63d09dc6

Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States — Europe PMC PMID:33180804

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/33180804
DOI: 10.1371/journal.pone.0241989
License (as archived): CC0-1.0
Archived: 2026-11-06T23:03:35.574Z
SHA-256 of the archived text: ef6e30b566d7ff4a32c0afd4cd9e08a9acf4cca30f821da8749c9504b938e94e
Stable URL of this page: https://metraipolis.com/documento/dc_06ca63d09dc6

How to cite

Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States — Europe PMC PMID:33180804 — Europe PMC (en), https://europepmc.org/article/MED/33180804 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_06ca63d09dc6 (Metraipolis archive dc_06ca63d09dc6, sha256 ef6e30b566d7ff4a32c0afd4cd9e08a9acf4cca30f821da8749c9504b938e94e)

BibTeX

@misc{dc06ca63d09dc6,
  title = {Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States — Europe PMC PMID:33180804},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/33180804},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_06ca63d09dc6; sha256 ef6e30b566d7ff4a32c0afd4cd9e08a9acf4cca30f821da8749c9504b938e94e},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/33180804. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Introduction: Eculizumab is a licensed treatment for several rare, complement-mediated diseases. Eculizumab use is associated with an approximately 2,000-fold increased meningococcal disease risk. In the United States, meningococcal vaccines are recommended for eculizumab recipients but there are no recommendations on use of long-term antibiotic prophylaxis. We describe characteristics of and meningococcal vaccine and antibiotic receipt in U.S. eculizumab recipients to inform meningococcal disease prevention strategies. Methods: Persons in the IBM® MarketScan® Research Databases with ≥1 claim for eculizumab injection during 2007-2017 were included. Indication for eculizumab use, meningococcal vaccine receipt, and antibiotic receipt were assessed using International Classification of Diseases-9/10 diagnosis codes, vaccine administration procedure codes, and antibiotic codes from pharmacy claims, respectively. Results: Overall 696 persons met the inclusion criteria. Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) were the most common indications for eculizumab use (41% and 37%, respectively); 20% had an undetermined indication. From June 2015 through December 2017, 28% (41/148) of continuously-enrolled patients received ≥1 serogroup B vaccine dose. For serogroup ACWY conjugate vaccine, 45% (91/201) of patients received ≥1 dose within five years of their most recent eculizumab dose, as recommended. Of eculizumab recipients with outpatient prescription data, 7% (41/579) received antibiotics for ≥50% of the period of increased risk for meningococcal disease. Conclusion: Many eculizumab recipients had an undetermined indication for eculizumab use; few were up-to-date for recommended meningococcal vaccines or were prescribed antibiotics long-term. These findings can inform further investigation of how to best protect this population from meningococcal disease.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2020 (prima pubblicazione 2020-11-12).
Identificativi: PMID 33180804 · PMCID PMC7660549 · DOI 10.1371/journal.pone.0241989.
Pagina: https://europepmc.org/article/MED/33180804 — https://doi.org/10.1371/journal.pone.0241989. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-06T23:00:02.249Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.